Cargando…

Odanacatib, a New Drug for the Treatment of Osteoporosis: Review of the Results in Postmenopausal Women

Osteoclasts are specialized cells that initiate the process of bone resorption, which has two phases, dissolution of the mineral component and degradation of the organic matrix, in which cathepsin K plays a key role. Cathepsin K inhibitors, which block the activity of cathepsin on bone resorption la...

Descripción completa

Detalles Bibliográficos
Autores principales: Pérez-Castrillón, José Luis, Pinacho, Florentino, De Luis, Daniel, Lopez-Menendez, María, Dueñas Laita, Antonio
Formato: Texto
Lenguaje:English
Publicado: SAGE-Hindawi Access to Research 2010
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2951121/
https://www.ncbi.nlm.nih.gov/pubmed/20948576
http://dx.doi.org/10.4061/2010/401581
_version_ 1782187690411687936
author Pérez-Castrillón, José Luis
Pinacho, Florentino
De Luis, Daniel
Lopez-Menendez, María
Dueñas Laita, Antonio
author_facet Pérez-Castrillón, José Luis
Pinacho, Florentino
De Luis, Daniel
Lopez-Menendez, María
Dueñas Laita, Antonio
author_sort Pérez-Castrillón, José Luis
collection PubMed
description Osteoclasts are specialized cells that initiate the process of bone resorption, which has two phases, dissolution of the mineral component and degradation of the organic matrix, in which cathepsin K plays a key role. Cathepsin K inhibitors, which block the activity of cathepsin on bone resorption lacunae, may be a new therapeutic option in osteoporosis. Odanacatib is a nonpeptidic biaryl inhibitor of cathepsin K. Two studies have evaluated the efficacy and safety of odanacatib, a phase I study to determine the dose and a phase II study of safety and efficacy. Due to the long half-life of odanacatib and the similar effects of different doses on bone remodeling markers, a weekly dosage was chosen for the phase II trail, with the best results being obtained with a dose of 50 mg. At 36 months, increases in bone mineral density similar to those produced by other powerful antiresorptive drugs (zoledronate and denosumab) were observed but there were differences in the behaviour of bone remodeling markers. Data on fractures from the phase III trial currently in development are required to confirm these possible advantages.
format Text
id pubmed-2951121
institution National Center for Biotechnology Information
language English
publishDate 2010
publisher SAGE-Hindawi Access to Research
record_format MEDLINE/PubMed
spelling pubmed-29511212010-10-14 Odanacatib, a New Drug for the Treatment of Osteoporosis: Review of the Results in Postmenopausal Women Pérez-Castrillón, José Luis Pinacho, Florentino De Luis, Daniel Lopez-Menendez, María Dueñas Laita, Antonio J Osteoporos Review Article Osteoclasts are specialized cells that initiate the process of bone resorption, which has two phases, dissolution of the mineral component and degradation of the organic matrix, in which cathepsin K plays a key role. Cathepsin K inhibitors, which block the activity of cathepsin on bone resorption lacunae, may be a new therapeutic option in osteoporosis. Odanacatib is a nonpeptidic biaryl inhibitor of cathepsin K. Two studies have evaluated the efficacy and safety of odanacatib, a phase I study to determine the dose and a phase II study of safety and efficacy. Due to the long half-life of odanacatib and the similar effects of different doses on bone remodeling markers, a weekly dosage was chosen for the phase II trail, with the best results being obtained with a dose of 50 mg. At 36 months, increases in bone mineral density similar to those produced by other powerful antiresorptive drugs (zoledronate and denosumab) were observed but there were differences in the behaviour of bone remodeling markers. Data on fractures from the phase III trial currently in development are required to confirm these possible advantages. SAGE-Hindawi Access to Research 2010-06-14 /pmc/articles/PMC2951121/ /pubmed/20948576 http://dx.doi.org/10.4061/2010/401581 Text en Copyright © 2010 José Luis Pérez-Castrillón et al. https://creativecommons.org/licenses/by/3.0/ This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
spellingShingle Review Article
Pérez-Castrillón, José Luis
Pinacho, Florentino
De Luis, Daniel
Lopez-Menendez, María
Dueñas Laita, Antonio
Odanacatib, a New Drug for the Treatment of Osteoporosis: Review of the Results in Postmenopausal Women
title Odanacatib, a New Drug for the Treatment of Osteoporosis: Review of the Results in Postmenopausal Women
title_full Odanacatib, a New Drug for the Treatment of Osteoporosis: Review of the Results in Postmenopausal Women
title_fullStr Odanacatib, a New Drug for the Treatment of Osteoporosis: Review of the Results in Postmenopausal Women
title_full_unstemmed Odanacatib, a New Drug for the Treatment of Osteoporosis: Review of the Results in Postmenopausal Women
title_short Odanacatib, a New Drug for the Treatment of Osteoporosis: Review of the Results in Postmenopausal Women
title_sort odanacatib, a new drug for the treatment of osteoporosis: review of the results in postmenopausal women
topic Review Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2951121/
https://www.ncbi.nlm.nih.gov/pubmed/20948576
http://dx.doi.org/10.4061/2010/401581
work_keys_str_mv AT perezcastrillonjoseluis odanacatibanewdrugforthetreatmentofosteoporosisreviewoftheresultsinpostmenopausalwomen
AT pinachoflorentino odanacatibanewdrugforthetreatmentofosteoporosisreviewoftheresultsinpostmenopausalwomen
AT deluisdaniel odanacatibanewdrugforthetreatmentofosteoporosisreviewoftheresultsinpostmenopausalwomen
AT lopezmenendezmaria odanacatibanewdrugforthetreatmentofosteoporosisreviewoftheresultsinpostmenopausalwomen
AT duenaslaitaantonio odanacatibanewdrugforthetreatmentofosteoporosisreviewoftheresultsinpostmenopausalwomen